Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) Return on Sales: 2016-2025

Historic Return on Sales for Seres Therapeutics (MCRB) over the last 7 years, with Sep 2025 value amounting to -945.89%.

  • Seres Therapeutics' Return on Sales was N/A to -945.89% in Q3 2025 from the same period last year, while for Sep 2025 it was -945.89%, marking a year-over-year change of. This contributed to the annual value of 0.60% for FY2023, which is 994.00% up from last year.
  • As of Q3 2025, Seres Therapeutics' Return on Sales stood at -945.89%, which was down 434,861.23% from 0.22% recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Return on Sales registered a high of 0.22% during Q1 2024, and its lowest value of -945.89% during Q3 2025.
  • Moreover, its 3-year median value for Return on Sales was -0.47% (2023), whereas its average is -163.17%.
  • As far as peak fluctuations go, Seres Therapeutics' Return on Sales tumbled by 3,156bps in 2023, and later surged by 3,239bps in 2024.
  • Over the past 5 years, Seres Therapeutics' Return on Sales (Quarterly) stood at -0.45% in 2021, then slumped by 2,521bps to -25.66% in 2022, then spiked by 2,537bps to -0.29% in 2023, then soared by 3,239bps to 0.22% in 2024, then reached -945.89% in 2025.
  • Its last three reported values are -945.89% in Q3 2025, 0.22% for Q1 2024, and -0.29% during Q4 2023.